Moderna, Inc. (MRNA)
Moderna shares jump on insider stock purchases
Moderna Inc (NASDAQ:MRNA, ETR:0QF) shares moved higher after it was disclosed the company insiders have purchased $6 million in shares. According to filings with the Securities and Exchange Commission (SEC), CEO Stephane Bancel purchased 160,314 shares for $5 million.
Coatue's Philippe Laffont Just Bought Shares of This Beaten-Down Growth Stock That Wall Street Predicts Will Soar 80%
The S&P 500 has soared in recent times, delivering two consecutive years of double-digit gains, and investors -- from billionaires to small retail investors -- have piled into some of the biggest winners. I'm talking about technology stocks, and, more specifically, players operating in the high-growth area of artificial intelligence (AI).
Moderna Tumbles As RFK Jr. Reportedly Mulls Pulling $590 Million In Bird Flu Funds
Moderna stock toppled Thursday on reports the Trump administration is considering pulling bird flu vaccine funding. The post Moderna Tumbles As RFK Jr. Reportedly Mulls Pulling $590 Million In Bird Flu Funds appeared first on Investor's Business Daily.
Moderna's stock stumbles on report HHS is reviewing a $590 million bird-flu-vaccine award
The Trump administration is reviewing a contract extended to Moderna in the final days of the Biden administration.
Can Moderna's Aggressive Cost Cuts Help Turn Things Around for Its Stock?
Moderna (MRNA -6.67%) became a hot investment during the pandemic as its COVID vaccine made investors bullish on its future. But you may be surprised to learn that now you can buy the stock around the levels it was at in April 2020 -- even before regulators approved its vaccine.
Trump administration weighs pulling funding for Moderna bird flu vaccine, Bloomberg News reports
U.S. health officials are reevaluating a $590 million contract that was awarded to Moderna for the development of its bird flu vaccine, Bloomberg News reported on Wednesday, citing sources.
Moderna (MRNA) International Revenue Performance Explored
Explore how Moderna's (MRNA) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.
Moderna and Other Vaccine Stocks Climb Amid Concerns About Coronavirus Study in China
Concerns about coronavirus news out of China may have moved some vaccine-maker and travel stocks Friday.
Moderna and Other Vaccine Stocks Climb After Coronavirus News From China
Concerns about coronavirus news out of China may have moved some vaccine-maker and travel stocks Friday.
Will Moderna Stock Drop to $25? 1 Wall Street Analyst Thinks So.
In the dark days of the coronavirus pandemic, Moderna (MRNA 0.42%) was a ray of light in more ways than one. The healthcare company's innovative Spikevax was one of the go-to vaccines that sped to market, not only protecting hundreds of millions of people from COVID-19, but also producing gobs of revenue and healthy profits.
Moderna: A Generational Opportunity for Investors in 2025
As bad as it may look on the charts, Moderna's NASDAQ: MRNA post-COVID let-down and market reset are over. The company stock trades at rock bottom in early 2025 and presents a generational opportunity in cutting-edge biotech.
Moderna shares move higher as investors look beyond Q4 losses to pipeline potential
Moderna Inc (NASDAQ:MRNA, ETR:0QF) shares added more than 8% during Tuesday's session as investors remained optimistic about the company's long-term strategy following mixed fourth quarter earnings. The company last week reported a wider-than-expected loss for Q4, as revenue surpassed expectations.
